virus-activated killer immune cell therapy (Binhui Biopharmaceutical)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Namevirus-activated killer immune cell therapy (Binhui Biopharmaceutical)
Drug Alias Nameultraviolet-inactivated oncolytic herpes simplex virus type 2-activated killer immune cell therapy (Binhui Biopharmaceutical)VAKUV-oHSV2-activated killer immune cell therapy (Binhui Biopharmaceutical)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyBiologics > Oncolytic virus
Mechanisms of ActionNatural killer cells stimulantsImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsAscitesPleural DiseasesPeritoneal Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesWuhan Binhui Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWuhan Binhui Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsAscitesPleural DiseasesPeritoneal Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A